Study analysis · Journal of hypertension · 2025
Aiming for a systolic blood pressure of 120 may lower relative risk of strokes, heart attacks, and death—but more people faint, and absolute benefits are unknown.
A review of 39,811 people found that intensive blood pressure control (≤120) lowered relative risk of cardiovascular events and death compared with standard control (≤140), but increased relative risk of fainting; absolute risk changes were not reported.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study combines results from several randomized trials, which are the best way to test if a treatment works. But because we only have a short summary, we can't be sure how well those trials were done, so we can't say for sure that intensive blood pressure control causes fewer heart attacks and strokes; we can only say it seems linked.
What’s the bottom line?
A study combined results from 6 trials with nearly 40,000 people to see if aiming for a lower blood pressure goal (120) is better than the standard goal (140).
How strong is this study?
The study looks at a lot of people (almost 40,000) from multiple trials, which is good. But we don't have the full details, so we don't know if there were problems like bias or if the trials were done properly. That means we should be careful about trusting the results too much.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
25 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=39811)+20/20
- Follow-upno follow-up reported
100 / 100
54 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
This design can establish causation. Abstract only; full methodology not available. While design is systematic review of RCTs, risk of bias, heterogeneity, and protocol not verifiable, so causation cannot be confirmed from abstract alone.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding statement was provided in the abstract, so potential conflicts cannot be assessed.
The provided text is only an abstract and lacks COI, funding, and author affiliation disclosures. No industry involvement can be confirmed or ruled out.
Key takeaways
- 01
People with the lower goal had a 19% lower relative risk of stroke, 17% lower relative risk of heart attack, 27% lower relative risk of dying from heart problems, and 13% lower relative risk of dying from any cause.
- 02
But they were 54% more likely to faint (syncope).
- 03
The absolute risks (like how many extra people per 1000) were not reported.
- 04
The study didn't provide enough information to calculate the absolute risk difference—meaning we don't know how many people would need to be treated to prevent one event or how many extra fainting episodes would occur.
- 05
The relative reductions are significant, but the real-world impact is unclear without absolute numbers.
Practical takeaways
If you have hypertension, discuss with your clinician whether an intensive systolic target (≤120) is appropriate for you, especially if you are at high cardiovascular risk.
The abstract does not report absolute benefits or harms, and full methodology is not available; individual decisions require clinical context.
low confidenceIf you are on an intensive BP target, ask about syncope risk and fall prevention.
Syncope relative risk increased, but the absolute increase was not reported; not everyone will faint.
low confidenceDo not change blood pressure medications based solely on this abstract; wait for full guidelines or clinician advice.
This analysis is based on an abstract only, with no full text available.
low confidenceWhy this study matters
Intensive BP control cut relative risk of major events
In 6 RCTs of 39,811 hypertensive adults (mean age 64.8), aiming for systolic ≤120 vs ≤140 was linked to lower relative risk: stroke RR 0.81 (19% relative reduction), heart attack RR 0.83 (17% relative reduction), cardiovascular death RR 0.73 (27% relative reduction), and all-cause death RR 0.87 (13% relative reduction). Absolute risk reductions were not reported.
Many people have high blood pressure, and these relative reductions sound large, but without absolute numbers we cannot know how many people actually benefit.
The fainting tradeoff
Intensive control had a higher relative risk of syncope (RR 1.54; 54% relative increase). No significant differences were found for bradycardia (RR 1.12; 95% CI 0.70–1.77) or symptomatic hypotension (RR 2.25; 95% CI 0.61–8.24).
Tighter blood pressure control is not free—fainting can lead to falls and injuries, especially in older adults.
Absolute risk missing from the abstract
The abstract reports relative risks and confidence intervals but no absolute risk reductions, so numbers needed to treat or harm cannot be calculated from it. Full methodology is not available.
Without absolute numbers, headlines can make benefits and harms seem larger or smaller than they are for an individual.
Who was studied
This meta-analysis included 6 RCTs with 39,811 hypertensive patients, mean age 64.8 years. Follow-up duration, blinding, and control group details are not specified in the abstract.
Older hypertensive adults may not represent younger people or those with different health conditions.
Authors advocate intensive control
The authors conclude intensive systolic BP control “may offer substantial cardiovascular benefits with minimal adverse effects and should be considered in clinical practice,” despite absolute risks not being reported in the abstract.
Clinical practice recommendations based on an abstract alone deserve scrutiny, especially when harms are not fully quantified.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A study combined results from 6 trials with nearly 40,000 people to see if aiming for a lower blood pressure goal (120) is better than the standard goal (140).
Research results
People with the lower goal had a 19% lower relative risk of stroke, 17% lower relative risk of heart attack, 27% lower relative risk of dying from heart problems, and 13% lower relative risk of dying from any cause. But they were 54% more likely to faint (syncope). The absolute risks (like how many extra people per 1000) were not reported.
What this means - more context
The study didn't provide enough information to calculate the absolute risk difference—meaning we don't know how many people would need to be treated to prevent one event or how many extra fainting episodes would occur. The relative reductions are significant, but the real-world impact is unclear without absolute numbers.
To compare the effects of intensive (≤120 mmHg) versus standard (≤140 mmHg) systolic blood pressure control on cardiovascular outcomes in hypertensive patients.
In a meta-analysis of 6 RCTs (39,811 patients, mean age 64.8 years), intensive systolic BP control significantly reduced the relative risk of stroke (RR 0.81, 95% CI 0.74–0.90), myocardial infarction (RR 0.83, 95% CI 0.73–0.95), cardiovascular death (RR 0.73, 95% CI 0.58–0.91), and all-cause mortality (RR 0.87, 95% CI 0.76–0.99). However, syncope occurred more frequently with intensive control (RR 1.54, 95% CI 1.23–1.92). No significant differences were found for bradycardia or symptomatic hypotension. Absolute risk reductions were not reported.
Methods Used
Systematic search of three databases identified six randomized controlled trials (RCTs) including 39,811 hypertensive patients (mean age 64.8 years). Meta-analysis compared intensive (≤120 mmHg) versus standard (≤140 mmHg) systolic BP targets.
Main Finding
Intensive systolic BP control significantly reduced the relative risk of stroke by 19% (RR 0.81), myocardial infarction by 17% (RR 0.83), cardiovascular death by 27% (RR 0.73), and all-cause mortality by 13% (RR 0.87). Syncope risk increased by 54% relative (RR 1.54). Absolute risk reductions were not reported. The authors conclude that intensive control may offer substantial cardiovascular benefits with minimal adverse effects.
Confidence Level
Limited - based on abstract only, full methodology not available.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Absolute risk reductions not reported
- •Potential heterogeneity and publication bias not addressed in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
If you have hypertension, discuss with your clinician whether an intensive systolic target (≤120) is appropriate for you, especially if you are at high cardiovascular risk.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Human Meta-Analysis
Subject
Moderate probability
on the GRADE evidence scale
This study combines results from several randomized trials, which are the best way to test if a treatment works. But because we only have a short summary, we can't be sure how well those trials were done, so we can't say for sure that intensive blood pressure control causes fewer heart attacks and strokes; we can only say it seems linked.
Strengths
- Meta-analysis of randomized controlled trials
- Large sample size (39,811 patients)
- Systematic search of three databases
Weaknesses
- Full methodology not available - based on abstract only
- Randomization and blinding of included RCTs not described
- Risk of bias assessment not reported
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A study combined results from 6 trials with nearly 40,000 people to see if aiming for a lower blood pressure goal (120) is better than the standard goal (140).
Research results
People with the lower goal had a 19% lower relative risk of stroke, 17% lower relative risk of heart attack, 27% lower relative risk of dying from heart problems, and 13% lower relative risk of dying from any cause. But they were 54% more likely to faint (syncope). The absolute risks (like how many extra people per 1000) were not reported.
What this means - more context
The study didn't provide enough information to calculate the absolute risk difference—meaning we don't know how many people would need to be treated to prevent one event or how many extra fainting episodes would occur. The relative reductions are significant, but the real-world impact is unclear without absolute numbers.
To compare the effects of intensive (≤120 mmHg) versus standard (≤140 mmHg) systolic blood pressure control on cardiovascular outcomes in hypertensive patients.
In a meta-analysis of 6 RCTs (39,811 patients, mean age 64.8 years), intensive systolic BP control significantly reduced the relative risk of stroke (RR 0.81, 95% CI 0.74–0.90), myocardial infarction (RR 0.83, 95% CI 0.73–0.95), cardiovascular death (RR 0.73, 95% CI 0.58–0.91), and all-cause mortality (RR 0.87, 95% CI 0.76–0.99). However, syncope occurred more frequently with intensive control (RR 1.54, 95% CI 1.23–1.92). No significant differences were found for bradycardia or symptomatic hypotension. Absolute risk reductions were not reported.
Methods Used
Systematic search of three databases identified six randomized controlled trials (RCTs) including 39,811 hypertensive patients (mean age 64.8 years). Meta-analysis compared intensive (≤120 mmHg) versus standard (≤140 mmHg) systolic BP targets.
Main Finding
Intensive systolic BP control significantly reduced the relative risk of stroke by 19% (RR 0.81), myocardial infarction by 17% (RR 0.83), cardiovascular death by 27% (RR 0.73), and all-cause mortality by 13% (RR 0.87). Syncope risk increased by 54% relative (RR 1.54). Absolute risk reductions were not reported. The authors conclude that intensive control may offer substantial cardiovascular benefits with minimal adverse effects.
Confidence Level
Limited - based on abstract only, full methodology not available.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Absolute risk reductions not reported
- •Potential heterogeneity and publication bias not addressed in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
If you have hypertension, discuss with your clinician whether an intensive systolic target (≤120) is appropriate for you, especially if you are at high cardiovascular risk.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Human Meta-Analysis
Subject
Moderate probability
on the GRADE evidence scale
This study combines results from several randomized trials, which are the best way to test if a treatment works. But because we only have a short summary, we can't be sure how well those trials were done, so we can't say for sure that intensive blood pressure control causes fewer heart attacks and strokes; we can only say it seems linked.
Strengths
- Meta-analysis of randomized controlled trials
- Large sample size (39,811 patients)
- Systematic search of three databases
Weaknesses
- Full methodology not available - based on abstract only
- Randomization and blinding of included RCTs not described
- Risk of bias assessment not reported
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study looks at a lot of people (almost 40,000) from multiple trials, which is good. But we don't have the full details, so we don't know if there were problems like bias or if the trials were done properly. That means we should be careful about trusting the results too much.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
25 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=39811)+20/20
- Follow-upno follow-up reported
100 / 100
54 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
This design can establish causation. Abstract only; full methodology not available. While design is systematic review of RCTs, risk of bias, heterogeneity, and protocol not verifiable, so causation cannot be confirmed from abstract alone.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding statement was provided in the abstract, so potential conflicts cannot be assessed.
The provided text is only an abstract and lacks COI, funding, and author affiliation disclosures. No industry involvement can be confirmed or ruled out.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
6 researchersIf this is your work, this is how we attribute it on Fit Body Science. Vitória Martins Prizão is listed as the lead author.
- Universidade Estadual de Maringá
Cited in 1 claim